Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer

Mapping Intimacies ◽

10.1158/1538-7445.sabcs17-pd3-13 ◽

2018 ◽

Author(s):

K Kalinsky ◽

JJ Harding ◽

A DeMichele ◽

JR Infante ◽

K Gogineni ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Download Full-text

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-4813-z ◽

2018 ◽

Vol 171 (1) ◽

pp. 111-120 ◽

Author(s):

Aditya Bardia ◽

Ayca Gucalp ◽

Noashir DaCosta ◽

Nashat Gabrail ◽

Michael Danso ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Androgen Receptor ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Phase 1 Study ◽

Estrogen Receptor Positive ◽

Receptor Inhibitor

Download Full-text

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.1011 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 1011-1011 ◽

Author(s):

Angela DeMichele ◽

James J. Harding ◽

Melinda L. Telli ◽

Pamela N. Munster ◽

Rana McKay ◽

...

Keyword(s):

Breast Cancer ◽

Small Molecule ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Small Molecule Inhibitor ◽

Phase 1 Study ◽

Molecule Inhibitor

Download Full-text

Abstract P6-18-35: A phase 1 study of erlotinib and metformin in advanced triple negative breast cancer

10.1158/1538-7445.sabcs18-p6-18-35 ◽

2019 ◽

Author(s):

KM Fenn ◽

MA Maurer ◽

SM Lee ◽

KD Crew ◽

MS Trivedi ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Download Full-text

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

Investigational New Drugs ◽

10.1007/s10637-015-0244-4 ◽

2015 ◽

Vol 33 (4) ◽

pp. 890-894 ◽

Author(s):

Zahi Mitri ◽

Cansu Karakas ◽

Caimiao Wei ◽

Brian Briones ◽

Holly Simmons ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Cdk Inhibitor ◽

Download Full-text

Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.08.004 ◽

2020 ◽

Vol 20 (1) ◽

pp. 80-86

Author(s):

Kathleen Fenn ◽

Matthew Maurer ◽

Shing M. Lee ◽

Katherine D. Crew ◽

Meghna S. Trivedi ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Download Full-text

Abstract P6-13-21: Phase 1 study of GR antagonist mifepristone (M) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients (pts) with GR-positive triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs15-p6-13-21 ◽

2016 ◽

Author(s):

S Wilks ◽

M Modiano ◽

A Spira ◽

C Becerra ◽

J Walling ◽

...

Keyword(s):

Breast Cancer ◽

Solid Tumors ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Download Full-text

Mifepristone (MIFE), a glucocorticoid receptor (GR) antagonist, in combination with eribulin (E) in advanced solid tumors: A phase 1 study with dose expansion in patients (pts) with triple-negative breast cancer (TNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e12070 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e12070-e12070 ◽

Author(s):

Rita Nanda ◽

Sharon Wilks ◽

Manuel R. Modiano ◽

Alexander I. Spira ◽

Carlos Becerra ◽

...

Keyword(s):

Breast Cancer ◽

Glucocorticoid Receptor ◽

Solid Tumors ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Download Full-text

Faculty Opinions recommendation of Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734027977.793562867 ◽

2019 ◽

Author(s):

Sherene Loi

Keyword(s):

Breast Cancer ◽

Clinical Outcomes ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Download Full-text

Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC)

10.1158/1538-7445.sabcs16-p6-11-05 ◽

2017 ◽

Author(s):

AM DeMichele ◽

JJ Harding ◽

ML Telli ◽

P Münster ◽

RR McKay ◽

...

Keyword(s):

Breast Cancer ◽

Small Molecule ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Small Molecule Inhibitor ◽

Phase 1 Study ◽

Molecule Inhibitor

Download Full-text

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2013.05.020 ◽

2013 ◽

Vol 49 (14) ◽

pp. 2972-2978 ◽

Author(s):

Joyce F. Liu ◽

Sara M. Tolaney ◽

Michael Birrer ◽

Gini F. Fleming ◽

Mary K. Buss ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 1 ◽

Phase 1 Trial ◽

Polymerase Inhibitor

Download Full-text